{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:04:09Z","timestamp":1791857049912,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T00:00:00Z","timestamp":1401148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s11096-014-9959-0","type":"journal-article","created":{"date-parts":[[2014,5,26]],"date-time":"2014-05-26T06:54:53Z","timestamp":1401087293000},"page":"779-786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin"],"prefix":"10.1007","volume":"36","author":[{"given":"Natalia","family":"Riva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Caceres","family":"Guido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Iba\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Licciardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Mato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Monteverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Schaiquevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,27]]},"reference":[{"key":"9959_CR1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00007890-200205151-00002","volume":"73","author":"B Nashan","year":"2002","unstructured":"Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of Neoral C(2) monitoring: a review. Transplantation. 2002;73:S3\u201311.","journal-title":"Transplantation"},{"key":"9959_CR2","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","volume":"351","author":"P Halloran","year":"2004","unstructured":"Halloran P. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715\u201329.","journal-title":"N Engl J Med"},{"key":"9959_CR3","doi-asserted-by":"crossref","unstructured":"Eljebari H, Ben Fradj N, Salouage I, Gaies E, Trabelsi S, Jebabli N, et al. Estimation of abbreviated cyclosporine A area under the concentration-time curve in allogenic stem cell transplantation after oral administration. J Transplant. 2012; 2012:342701.","DOI":"10.1155\/2012\/342701"},{"issue":"6","key":"9959_CR4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1399-3046.2006.00577.x","volume":"10","author":"B T\u00f6nshoff","year":"2006","unstructured":"T\u00f6nshoff B, H\u00f6cker B. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Pediatr Transplant. 2006;10(6):721\u20139.","journal-title":"Pediatr Transplant"},{"issue":"8","key":"9959_CR5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1399-3046.2010.01409.x","volume":"14","author":"SM Pollock-Barziv","year":"2010","unstructured":"Pollock-Barziv SM, Finkelstein Y, Manlhiot C, Dipchand AI, Hebert D, Ng VL, et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant. 2010;14(8):968\u201375.","journal-title":"Pediatr Transplant"},{"issue":"9308","key":"9959_CR6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(02)07875-3","volume":"359","author":"R Margreiter","year":"2002","unstructured":"Margreiter R. European tacrolimus vs ciclosporin microemulsion renal transplantation study group efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet. 2002;359(9308):741\u20136.","journal-title":"Lancet"},{"issue":"6","key":"9959_CR7","first-page":"441","volume":"37","author":"N Riva","year":"2013","unstructured":"Riva N, C\u00e1ceres Guido P, Rousseau M, Dip M, Monteverde M, Imventarza O, et al. Pharmacovigilance of calcineurin inhibitor in peidatric kidney and liver transplantation. Farm Hosp. 2013;37(6):441\u20139.","journal-title":"Farm Hosp"},{"issue":"3","key":"9959_CR8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1034\/j.1399-0012.1999.130301.x","volume":"13","author":"ML Henry","year":"1999","unstructured":"Henry ML. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant. 1999;13(3):209\u201320.","journal-title":"Clin Transplant"},{"issue":"4","key":"9959_CR9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1208\/s12248-013-9528-9","volume":"15","author":"SK Sy","year":"2013","unstructured":"Sy SK, Heuberger J, Shilbayeh S, Conrado DJ, Derendorf H. A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation. AAPS J. 2013;15(4):1189\u201399.","journal-title":"AAPS J"},{"key":"9959_CR10","doi-asserted-by":"crossref","first-page":"480642","DOI":"10.1155\/2011\/480642","volume":"2011","author":"AK Singh","year":"2011","unstructured":"Singh AK, Narsipur SS. Cyclosporine: a commentary on brand versus generic formulation exchange. J Transplant. 2011;2011:480642.","journal-title":"J Transplant."},{"issue":"4","key":"9959_CR11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1432-2277.2005.00078.x","volume":"18","author":"D Cattaneo","year":"2005","unstructured":"Cattaneo D, Perico N, Remuzzi G. Generic cyclosporine formulations: more open questions than answers. Transpl Int. 2005;18(4):371\u20138.","journal-title":"Transpl Int"},{"issue":"7","key":"9959_CR12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/TP.0b013e3182445e9d","volume":"93","author":"JJ Harrison","year":"2012","unstructured":"Harrison JJ, Schiff JR, Coursol CJ, Daley CJ, Dipchand AI, Heywood NM, et al. Generic immunosuppression in solid organ transplantation: a Canadian perspective. Transplantation. 2012;93(7):657\u201365.","journal-title":"Transplantation"},{"issue":"12","key":"9959_CR13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1432-2277.2011.01378.x","volume":"24","author":"T Gelder Van","year":"2011","unstructured":"Van Gelder T. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. Transpl Int. 2011;24(12):1135\u201341.","journal-title":"Transpl Int"},{"issue":"3","key":"9959_CR14","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1600-6143.2011.03876.x","volume":"12","author":"M Latran","year":"2012","unstructured":"Latran M. Response to Klintmalm on the use of generic immunosuppression. Am J Transplant. 2012;12(3):791.","journal-title":"Am J Transplant"},{"issue":"5","key":"9959_CR15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1373\/clinchem.2009.138693","volume":"56","author":"P Marquet","year":"2010","unstructured":"Marquet P. Counterpoint: Is pharmacokinetic or pharmacodynamic monitoring of calcineurin inhibition therapy necessary? Clin Chem. 2010;56(5):736\u20139.","journal-title":"Clin Chem"},{"issue":"1","key":"9959_CR16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/FTD.0b013e3180310f9d","volume":"29","author":"S Irtan","year":"2007","unstructured":"Irtan S, Saint-Marcoux F, Rousseau A, Zhang D, Leroy V, Marquet P, et al. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit. 2007;29(1):96\u2013102.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"9959_CR17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.transproceed.2008.11.002","volume":"41","author":"P Troncoso","year":"2009","unstructured":"Troncoso P, Ortiz AM, Jara A, Vilches S. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values. Transplant Proc. 2009;41(1):127\u201330.","journal-title":"Transplant Proc."},{"issue":"4","key":"9959_CR18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1681\/ASN.V124828","volume":"12","author":"K Mahalati","year":"2001","unstructured":"Mahalati K, Belitsky P, West K, Kiberd B, Fraser A, Sketris I, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol. 2001;12(4):828\u201333.","journal-title":"J Am Soc Nephrol"},{"key":"9959_CR19","unstructured":"NEORAL\u00ae Soft Gelatin Capsules (cyclosporine capsules, USP) MODIFIED and NEORAL\u00ae Oral Solution (cyclosporine oral solution, USP) MODIFIED. Prescribing Information. NOVARTIS. Reference ID: 3302945. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050715s033,050716s034lbl.pdf . Accessed 10 Feb 2014."},{"key":"9959_CR20","unstructured":"Certificados de especialidades medicinales emitidos - Monof\u00e1rmacos - Junio 2007. ANMAT. Available from: http:\/\/www.anmat.gov.ar\/ESPECMED\/junio\/certificados_monofarmacos_07.asp . Accessed 11 Feb 2014."},{"key":"9959_CR21","unstructured":"Drugs and money\u2014prices, affordability and cost containment. In: Dukes M, Haaijer-Ruskamp F, de Joncheere C, Rietveld A, editors. World Health Organization. Regional Office for Europe by IOS Press; 2003. pp. 137\u2013149. ISBN\u00a01 58603 334 4."},{"issue":"9","key":"9959_CR22","doi-asserted-by":"crossref","first-page":"e74399","DOI":"10.1371\/journal.pone.0074399","volume":"8","author":"WA Kaplan","year":"2013","unstructured":"Kaplan WA, Wirtz VJ, Stephens P. The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: a descriptive time series analysis. PLoS ONE. 2013;8(9):e74399.","journal-title":"PLoS ONE"},{"issue":"11","key":"9959_CR23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/phar.1130","volume":"32","author":"M Spence","year":"2012","unstructured":"Spence M, Nguyen L, Hui R, Chan J. Evaluation of clinical and safety outcomes associated with conversion from brand name to generic tacrolimus in transplant recipients enrolled in an integrated health care system. Pharmacotherapy. 2012;32(11):981\u20137.","journal-title":"Pharmacotherapy."},{"issue":"10","key":"9959_CR24","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/j.1600-6143.2012.04174.x","volume":"12","author":"RR Alloway","year":"2012","unstructured":"Alloway RR, Sadaka B, Trofe-Clark J, Wiland A, Bloom RD. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant. 2012;12(10):2825\u201331.","journal-title":"Am J Transplant"},{"key":"9959_CR25","first-page":"1421","volume":"7","author":"M Kraeuter","year":"2013","unstructured":"Kraeuter M, Helmschrott M, Erbel C, Gleissner CA, Frankenstein L, Schmack B, et al. Conversion to generic cyclosporine A in stable chronic patients after heart transplantation. Drug Des Devel Ther. 2013;7:1421\u20136.","journal-title":"Drug Des Devel Ther."},{"key":"9959_CR26","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1038\/ki.2009.506","volume":"115","author":"S V\u00edtko","year":"2010","unstructured":"V\u00edtko S, Ferkl M. Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial. Kidney Int Suppl. 2010;115:S12\u20136.","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"9959_CR27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.12659\/AOT.881866","volume":"16","author":"M Niemczyk","year":"2011","unstructured":"Niemczyk M, Paczek L. Generic formulation of Cyclosporine A, Equoral\u00ae, in de novo kidney transplant recipients: five-year follow-up. Ann Transplant. 2011;16(2):59\u201362.","journal-title":"Ann Transplant."},{"issue":"1","key":"9959_CR28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.transproceed.2011.11.012","volume":"44","author":"J Al Wakeel","year":"2012","unstructured":"Al Wakeel J, Shaheen FA, Al Alfi A, Abbas Fagir EH, Iman A, Nampoory MR, et al. Cyclosporine microemulsion formulation (sigmasporin microral) effect as first-line immunosuppressant on renal functions at 3\u00a0years. Transplant Proc. 2012;44(1):94\u2013100.","journal-title":"Transplant Proc"},{"issue":"6","key":"9959_CR29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00228-004-0774-8","volume":"60","author":"A Johnston","year":"2004","unstructured":"Johnston A, Belitsky P, Frei U, Horvath J, Hoyer P, Helderman JH, et al. Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients. Eur J Clin Pharmacol. 2004;60(6):389\u201395.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"9959_CR30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00007890-199002000-00024","volume":"49","author":"J Dunn","year":"1990","unstructured":"Dunn J, Golden D, Van Buren CT, Lewis RM, Lawen J, Kahan BD. Causes of graft loss beyond two years in the cyclosporine era. Transplantation. 1990;49(2):349\u201353.","journal-title":"Transplantation"},{"issue":"2","key":"9959_CR31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2215\/CJN.03791106","volume":"2","author":"J Schiff","year":"2007","unstructured":"Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2(2):374\u201384.","journal-title":"Clin J Am Soc Nephrol."},{"key":"9959_CR32","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/00007890-200205151-00003","volume":"73","author":"G Levy","year":"2002","unstructured":"Levy G, Thervet E, Lake J, Uchida K. On behalf of the CONCERT group: patient management by Neoral C2 monitoring\u2014an international consensus statement. Transplantation. 2002;73:S12\u20138.","journal-title":"Transplantation"},{"issue":"5","key":"9959_CR33","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jpeds.2011.10.038","volume":"160","author":"VL Ng","year":"2012","unstructured":"Ng VL, Alonso EM, Bucuvalas JC, Cohen G, Limbers CA, Varni JW, et al. Health status of children alive 10\u00a0years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience. J Pediatr. 2012;160(5):820\u20136.","journal-title":"J Pediatr"},{"issue":"3","key":"9959_CR34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00148581-200709030-00005","volume":"9","author":"G Filler","year":"2007","unstructured":"Filler G. Calcineurin inhibitors in pediatric renal transplant recipients. Paediatr Drugs. 2007;9(3):165\u201374.","journal-title":"Paediatr Drugs"},{"key":"9959_CR35","unstructured":"Miranda I, Cherato M, Onofri A. Cobertura social para trasplantados subsidados por CUCAIBA en la red estatal. Available from: http:\/\/www.cucaiba.gba.gov.ar\/019.htm . Accessed 12 Feb 2014."},{"key":"9959_CR36","unstructured":"Calabria A. Analyzing the market for organs donation: evaluation of the introduction of incentives in Argentina. MPRA Paper No. 36044. 2011. Available from: http:\/\/mpra.ub.uni-muenchen.de\/36044\/1\/MPRA_paper_36044.pdf . Accessed 12 Feb 2014."},{"issue":"5","key":"9959_CR37","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.transproceed.2008.03.091","volume":"40","author":"JA Petan","year":"2008","unstructured":"Petan JA, Undre N, First MR, Saito K, Ohara T, Iwabe O, et al. Physiochemical properties of generic formulations of tacrolimus in Mexico. Transplant Proc. 2008;40(5):1439\u201342.","journal-title":"Transplant Proc."},{"key":"9959_CR38","unstructured":"Drug interactions. Micromedex Solutions. Available from: http:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/PFDefaultActionId\/evidencexpert.ShowDrugInteractionsResults . Accessed 14 Feb 2014."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-014-9959-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-014-9959-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-014-9959-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T18:22:27Z","timestamp":1649096547000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-014-9959-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,27]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["9959"],"URL":"https:\/\/doi.org\/10.1007\/s11096-014-9959-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,27]]}}}